Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation

Chronic graft-versus-host disease (cGVHD) is major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Ixazomib is an oral, second-generation, proteasome inhibitor (PI) that has been shown in preclinical models to prevent GVHD. We conducted a phase I/II tr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Biol Blood Marrow Transplant
Asıl Yazarlar: Chhabra, Saurabh, Visotcky, Alexis, Pasquini, Marcelo C., Zhu, Fenlu, Tang, Xiaoying, Zhang, Mei-Jie, Thompson, Robert, Abedin, Sameem, D’Souza, Anita, Dhakal, Binod, Drobyski, William R., Fenske, Timothy S., Jerkins, James H., Rizzo, J. Douglas, Runaas, Lyndsey, Saber, Wael, Shah, Nirav N., Shaw, Bronwen E., Horowitz, Mary M., Hari, Parameswaran N., Hamadani, Mehdi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7571859/
https://ncbi.nlm.nih.gov/pubmed/32653622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2020.07.005
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller